Manufacturer: La Pharma
Trade name: Qutace-SR
Strength: 100 mg
Active ingredient: Quetiapine
Category: Quetiapine is an atypical antipsychotic.
Pregnancy category: Quetiapine belongs to Australia therapeutic goods administration (TGA) pregnancy category: C AND US FDA pregnancy category: C
Uses: Qutace-SR100 mg tablet is used to treat schizophrenia, bipolar disorder, depression.
How to use: Qutace-SR100 mg tablet is taken by mouth with or without food. Do not suddenly stop taking the medicine as it works on the brain. Dose needs to be decreased gradually. Quetiapine along with other medicines is used to treat schizophrenia, bipolar disorder, depression. Warning: Quetiapine is not approved by FDA for use in geriatric patients with dementia.
Side Effects: drowsiness, dizziness, headache, light-headedness, tiredness, constipation, upset stomach, stomach pain, nausea and vomiting, weight gain, blurred vision, or dry mouth.
Dosage: Usual adult dose for schizophrenia: Initial dose is 25 mg orally twice a day. Dose can be increased in increments of 25 to 50 mg as advised by your doctor. Recommended dose is 150 to 750 mg orally per day in divided doses. Maximum daily dose is 750 mg. Extended-release tablets for schizophrenia: 300 mg orally once daily. Recommended dose is 400 to 800 mg orally daily. Maximum daily dose: 800 mg. Usual adult dose for bipolar disorder: Immediate release tablets - initial dose is 100 mg orally daily. Dose can be increased as per doctors advise. Recommended dose is 400 to 800 mg per day in divided doses. Maximum daily dose: 800 mg Extended-release tablets for bipolar disorder: 300 mg orally once daily. Recommended dose: 400 to 800 mg orally once a day. Maximum daily dose: 800 mg. Usual adult dose for depression: Extended release tablets: Initial dose is 50 mg orally once a day. Dose can be increased as per the doctor. Recommended dose is 150 mg to 300 mg orally once a day. Maximum daily dose is 300 mg.
Written by: : healthplus24.com team
Date last updated: August 6th, 2016
Subscribe to our email newsletter.